Differential Diagnosis, Causes, and Management of Hypercalcemia

Current Problems in Surgery

Volumn 34, Issue 6, 1997, Pages 456-523

  Chan, Fredriech K W ^a   Koberle, Lilia M C ^b   Thys Jacobs, Susan ^a   Bilezikian, John P ^c  

^a Columbia University ^*  (United States)

^b FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIFFERENTIAL DIAGNOSIS; HUMAN; HYPERCALCEMIA; INCIDENCE; PARATHYROIDECTOMY; PATIENT SELECTION; REVIEW; RISK FACTOR;

DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERCALCEMIA; INCIDENCE; PARATHYROIDECTOMY; PATIENT SELECTION; RISK FACTORS;

EID: 85052279817     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-3840(97)80008-1     Document Type: Article

References (253)

1. Robertson WG, Marshall RW. Ionized calcium in body fluids. Crit Rev Clin Lab Sei 1981;15:85-125.
2. Shane E, Bilezikian JP. Normal bone and mineral homeostasis. In: Bijvoet O, Fleisch HA, Canfield RE, Russell G, editors. Biphosphonates on bones. 1st ed. Amsterdam, The Netherlands: Eisevier Science; 1995. p. 3-21.
3. Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992:326:1196202.
4. Consensus Development Conference Panel: Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus development conference statement. Ann Intern Med 1991;! 14:593-7.
5. Fisken RA, Heath A, Bold AM. Hypercalcemia: a hospital survey. Q J Med 1984;196:405-18.
6. Edelson GW, KleerekoperM. Hyperparathyroidism and hypoparathyroidism. In: Rakel RE, editor. Conn's Current Therapy. Philadelphia: WB Saunders; 1992. p. 559-66.
7. Bilezikian JP. Etiologies and therapy of hypercalcemia. Endocrinol Metab Clin North Am 1989;18:389-413.
8. Fisken RA, Heath DA, Somers S, Bold AM. Hypercalcemia in hospital patients. Lancet 1981;l:202-6.
9. Stewart AF, Horst R, Deftos LJ, Cadman E, Lang R, Broadus AE. Biochemical evaluation of patients with cancer associated hypercalcemia. N Engl J Med 1980;303:137783.
10. Grill V, Martin TJ. Parathyroid hormone related protein as a cause hypercalcemia. In: Bilezikian JP, Levme MA, Marcus R, editors. The parathyroids. New York: Raven Press, LTD; 1994. p. 295-310.
11. Stewart AF, Vignery A, Silvergsite A, et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 1982;55:219-27.
12. McDonnell CD, Dunstan CR, Evans RA, et al. Quantitative bone histology in the hypercalcemia of malignant disease. J Clin Endocrinol Metab 1982;55:1066-72.
13. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP. Urinary hydroxypyridinium crosslinks OI2 collagen as markers or bone résorption in primary hyperparathyroidism. J Clin Endocrinol Metab 1992;74:481-6.
14. Fukumoto S, Matsumoto T, Yamoto H, et al. Suppression of serum 1,25 dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25 dihydroxyvitamin D3 production. Endocrinology 1989; 124:2057-62.
15. Schilling T, Pecherstorfer M, Blind E, Leidig G, Ziegler R, Raue F. Parathyroid hormone-related protein(PTHrP) does not regulate 1,25 dihydroxuvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab 1993;76:801-13.
16. Nakayama K, Fukumoto S, Takeda S, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996;81:607-11.
17. Heath H III, Hodgson SF, Kennedy MA. Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980;302:189-93.
18. Boonstra CE, Jackson CE. Serum calcium survey for hyperparathyroidism: results in 50,000 clinic patients. Am J Clin Pathol 1971;55:523-6.
19. Mallette LE, Malini S, Rappaport MP, Kirkland JL. Familial cystic parathyroid adenomatosis. Ann Intern Med 1987; 107:54-60.
20. Shane E, Bilezikian JP. Parathyroid carcinoma: a review of 62 patients. Endocr Rev 1982;3:218-26.
21. Wynne AG, Heerden JV, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine 1992;71:197-204.
22. Brown EM, Broadus AE, Brennan MF, et al. Direct comparison in vivo and in vitro of suppressibility of parathyroid function by calcium in primary hyperparathyroidism. J Clin Endocrinol Metab 1979;48:604-10.
23. Kifor O, Moore FD, Wang P, et al. Reduced immunostaining for the extracellular Ca2-sensing receptor in primary and urémie secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:1598-606.
24. ParfittAM, Braunstein GD, Katz A. Radiation-associated hyperparathyroidism: comparison of adenoma growth rates, inferred from weight and duration of latency, with prevalence of mitosis. J Clin Endocrinol Metab 1993 ;77:1318-22.
25. CrynsVL,YiSM,TaharaH, Gaz RD, Arnold A. Frequent loss of chromosome arm Ip DNA in parathyroid adenomas. Genes Chromosom Cancer 1995;13:9-17.
26. Tahara H, Cryns VL, Gaz RD, Arnold A. Chromosomal locations of new parathyroid tumor suppressor genes. J Bone Miner Res 1995;10(Suppl 1):S383.
27. Friedman E, Sakaguchi K, Bale AE, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type I. N Eng J Med 1989;321:213-8.
28. Motokura T, Bloom T, Kim HG, et al. A BCLl-linked candidate oncogene which is rearranged in parathyroid tumors encodes a novel cyclin. Nature 1991;350:512-5.
29. Hsi E, Zukerberg LR, Yang WI, Arnold A. Cyclin Dl expression in parathyroid adenomas: an immunohistochemical study. J Bone Miner Res 1995;10(Suppl 1):S383.
30. Arnold A. Molecular basis of hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids. New York: Raven Press; 1994. p. 407-21.
31. Carling T, Kindmark A, Hellman P, et al. Vitamin D receptor genotypes in primary hyperparathyroidism. Nature Medicine 1996; 1:1309-11.
32. Lim SK, Park YS, Park JM, et al. Lack of association between vitamin D receptor genotypes and osteoporosis in Koreans. J Clin Endocrinol Metab 1995;80:3677-81.
33. TokitaA, WatanabeT, MiuraY, et al. Vitamin D receptor gene RFLP and bone mineral density in Japanese. Bone 1995;16(Suppl 1):S17.
34. Sriussadaporn S. Genetics of osteoporosis: the role of vitamin D receptor genotypes. Symposiums of the Eighth Congress of the Asian Federation of Endocrine Societies, 1995:SY-0501.
35. Davis M. Hyperparathyroidism in X-linked hypophosphatemic osteomalacia. Clin Endocrinol 1995;42:205-6.
36. Silverberg SJ, Fitzpatrick LA, Bilezikian JP. Primary hyperparathyroidism. In: Becker KL editor. Principles and practice of endocrinology and metabolism. 2nd ed. Philadelphia: JB Lippincott; 1995. p. 512-9.
37. Bilezikian JP, Silverberg SJ, Gartenberg F, et al. Clinical presentation of primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids. New York: Raven Press; 1994. p. 457-70.
38. Silverberg SJ, Shane E, DeLaCruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989;4:283-91.
39. Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991;6(Suppl l):585-9.
40. Pfeilschifter J, Siegrist E, Wuster C, Blind E, Ziegler R. Serum levels of intact parathyroid hormone and alkaline phosphatase correlate with cortical and trabecular bone loss in primary hyperparathyroidism. Acta Endocrinol 1992;127:319-23.
41. Parisien MV, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990;70:930-8.
42. Parisien M, Mellish RWE, Silverberg S J, et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res 1992:7:913-20.
43. Parisien MV, Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. Bone disease in primary hyperparathyroidism. Endocrinol Metab Clin North Am 1990;19:19-34.
44. Bilezikian JP. Nephrolithiasis in primary hyperparathyroidism. In: Coe FL, Favus M J, Pak CYC, Parks JH, Preminger GM, editors. Kidney stones: medical and surgical treatment. Philadelphia: Lippincott-Raven; 1996. p. 783-802.
45. Silverberg S J, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990;89:327-34.
46. Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, Aurbach GD. The neuromuscular disease of hyperparathyroidism. Ann Intern Med 1974;80:182-94.
47. Türken SA, Cafferty M, Silverberg S J, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 1989;87:553-7.
48. Bilezikian JP, Aurbach GD, Connor TB, et al. Pseudogout following parathyroidectomy. Lancet 1973;l:445-7.
49. Mallette LE. Anemia in hypercalcémie hyperparathyroidism, renewed interest in an old observation. Arch Intern Med 1977;137:572-3.
50. Ljunghall S, Jakobsson S, Joborn C, et al. Longitudinal studies of mild primary hyperparathyroidism. J Bone Miner Res 1991;6(Suppl 2):S111.
51. Solomon BL, Schaaf M, Smallridge RC. Psychologic symptoms before and after parathyroid surgery. Am J Med 1994;96:101-6.
52. Fitzpatrick LA, Bilezikian JP. Acute primary hyperparathyroidisin: a review of 48 patients. Am J Med !987;82:275-82.
53. Brown EM, Pollak M, Seidman CE. et al. Calcium ion-sensing cell-surface receptors. N Engl Med 1995;333:234-40.
54. Nussbaum SR, Potts JT. Advances in immunoassays for parathyroid hormone: clinical applications to skeletal disorders of bone and mineral metabolism. In: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids. New York: Raven Press; 1994. p. 15769.
55. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SR Bilezikian JR Urinary hydroxypyridinium crosslinks of collagen as markers of bone résorption in primary hyperparathyroidism. J Clin Endocrinol Metab 1992;74:481-6.
56. Silverberg S J, Gartenberg F, Jacobs TP. et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab 1995:80:729-34.
57. Kaplan EL, Yoshiro T, Salti G. Primary hyperparathyroidism in the 1990s. Ann Surg 1992;215:300-17.
58. Doppman JL, Miller DL. Localization of parathyroid tumors in patients with asymptomatic hyperparathyroidism and no previous surgery. J Bone Miner Res 1991 ;6(Suppl 2):S153.
59. Akerstorm G, Malmaeus J, Bergstrom R. Surgical anatomy of human parathyroid glands. Surgery 1984;95:14-21.
60. Norton JA, Brennan MF, Wells SA. Surgical management of hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids. New York: Raven Press; 1994. p. 531-49.
61. Oertli D, Richter M, Kraenzlin M, et al. Parathyroidectomy in primary hyperparathyroidism: preoperative localization and routine biopsy of unaltered glands are not necessary. Surgery 1995;! 17:392-6.
62. LiVolsi VA, Hamilton R. Intraoperative assessment of parathyroid gland pathology: a common view from the surgeon and the pathologist. Am J Clin Pathol 1994;102;36573.
63. Brasier AR, Wang C, Nussbaum SR. Recovery of parathyroid hormone secretion after parathyroid adenomectomy. J Clin Endocrinol Metab 1988;61:495-500.
64. Weber C J, Sewell CW, McGarity WC. Persistent and recurrent sporadic primary hyperparathyroidism: histopathology, complications, and results of reoperation. Surgery 1994;! 16:991-8.
65. Mitchell BK, Kinder BK, Cornelius E, Stewart AF. Primary hyperparathyroidism: preoperative localization using technetium-sestamibi scanning. J Clin Endocrinol Metab 1995;80:7-10.
66. Mitchell BK, Merrell RC, Kinder BK. Localization studies in patients with hyperparathyroidism. Surg Clin North Am 1995;75:483-98.
67. McBiles M, Lambert AT, Cote MG, Kim SY. Sestamibi parathyroid imaging. Semin Nue Med 1995;25:221-34.
68. Doppman JL. Preoperative localization of parathyroid tissue in primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids. New York: Raven Press; 1994. p. 553-66.
69. Mclntyre RJ, Kumpe DA, Leichty RD. Reexploration and angiographie ablation for hyperparathyroidism. Arch Surg 1994; 129:499-503.
70. MacFarlane MP, Fraker DL, Shawker TH, et al. Use of preoperative fine needle aspiration in patients undergoing reoperation for primary hyperparathyroidism. Surgery 1994; 116:959-64.
71. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995;80:723-8.
72. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for a biphasic disease course. J Clin Endocrinol Metab 1988;67:12948.
73. Broadus AE, Magee JSI, Mallette LE, et al. A detailed evaluation of oral phosphate therapy in selected patients with primary hyperparathyroidism. J Clin Endocrinol Metab 1983;56:953-61.
74. Marcus R, Madvig P, Crim M, Pont A, Kosek J. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984;100:633-40.
75. Selby PL, Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 1986;314:14817.
76. Kaplan RA, Geho WB, Poindexter C, Haussler M, Dietz GW, Pak CYC. Metabolie effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol 1977; 17:410-9.
77. Shane E, Baquiran DC, Bilezikian JP. Effects of dichloromethylene diphosphonate on serum and urine calcium in primary hyperparathyroidism. Ann Intern Med 1981:95:23-7.
78. Adami S, Mian M, Bertoldo F, et al. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment. Clin Endocrinol 1990;33:391-7.
79. Janson S, Tisell LE, Lindstedt G, Lundberg PA. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Surgery 1991;! 10:480-6.
80. Silverberg S J, Thys-Jacobs S, Locker FG, Sanguinetti EL, MarriotTB. Bilezikian JP. The effect of the calcimetic drug NPS R-568 on parathyroid hormone secretion in primary hyperparathyroidism. J Bone Min Res 1996;ll(suppl):87A.
81. Quintensson T, Hellstrom K, Wengle B, Aloeryd A, Wikland B. Prevalence of hypercalcemia in a health screening in Stockholm. Acta Med Scand 1976;200:131-7.
82. Ralston SH, Gardner MD, Dryburg FJ, Jenkins AS, Boyle IT. Comparison of aminohydroxypropiledene diphosphonate, mithramycin and corticoid/calcitonin in the treatment of cancer-associated hypercalcemia. Lancet I985;2:l 180-2.
83. Singer FR. Role of bisphosphonate etidronate in the therapy of cancer related hypercalcemia. Semin Oncol 1990;17:34-9.
84. Eilon G, Mundy GR. Direct résorption of bone by human breast cancer cells in vitro. Nature 1978:276:726-8.
85. Goni MH, Tolls G. Hypercalcemia of cancer: an update. Anticancer Res 1993; 13:11560.
86. Mundy GR, Martin TJ. Hypercalcemia of malignancy: pathogenesis and treatment. Metab Clin Exp 1982;31:1247-77.
87. Albright F. Case records of the Massachusetts General Hospital. N Engl J Med 1941;255:789-1001.
88. Broadus AE, Mangin M, Ikeda K, et al. Humoral hypercalcemia of cancer: identification of a novel parathyroid hormone-like peptide. N Engl J Med 1988;319:556-63.
89. Isales C, Carcangiu ML, Stewart AF. Hypercalcemia of breast cancer: reassessment of the mechanism. Am J Med 1987;82:1143-7.
90. Gallagher SJ, Fraser WD, Patel U, et al. Breast cancer-associated hypercalcemia: a reassessment of renal calcium and phosphate handling. Ann Clin Biochem 1990:27:551-6.
91. Moseley GM, Kubota M, Diefenbach-Jagger H, et al. Parathyroid hormone related protein purified from a lung cancer cell line. Proc Natl Acad Sei U S A 1987;84:504852.
92. Strewler GJ, Stern GH, Jacobs JW, et al. PTH-like protein from human renal carcinoma cells: structural and functional homology with PTH. J Clin Invest 1987:80:18037.
93. Stewart AF, Wu T, Goumas D, Bentes WJ, Broadus AE. N-terminal aminoacid sequence of two novel tumor derived adenylate cyclaseostimulating proteins:identification of PTH-like and PTH-unlike domains. Biochem Biophys Res Commun 1987; 146:677-8.
94. Abou-Samra AB, Juppner H, Force T, et al. Expression cloning of a common receptor for PTH and PTHrP from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sei U S A 1992;89:2732-6.
95. Juppner H, Abou-Samra AB, Freeman Jr M, et al. A G protein-linked receptor for PTH and PTHrP. Science 1991;254:1024-6.
96. Ikeda K, Lu C, Weir EC, Magin M, Broadus AE. Transcriptional regulation of parathyroid hormone-related peptide gene by glucocorticoids and vitamin D in a human C-cell line. J Biol Chem 1989:264:15743-6.
97. Budayr AA, Nissenson RA, Klein RF, et al. Increased serum levels of a parathyroid hormone-like protein in malignancy associated hypercalcemia. Ann Intern Med 1989;! 11:807-12.
98. Godsal JN, Bentis WJ, Insogna KL, et al. Nephrogenous cAMP, adenylate cyclase stimulatory activity and the humoral hypercalcemia of malignancy. Recent Prog Horm Res 1986;40:705-50.
99. Burtis WJ, Brady TJ, Orloff JJ, et al. Immunochemical characterization of PTHrP in patients with humoral hypercalcemia of malignancy. N Engl J Med 1990;322:110612.
100. Motokura T, Fukumoto S, Matsumoto T, et al. PTHrP in adult T-cell leukemia-lymphoma. Ann Intern Med 1980;! 11:484-8.
101. Asa SL, Henderson J, Goltzman D, Dricker DJ. Parathyroid hormone-like peptide in normal and neoplastic endocrine tossues. J Clin Endocrinol Metab 1990:71:1112-8.
102. Kramer S, Reynolds Jr FH, Castillo M, Valenzuela DM, Thorikay M, Sorvillo LM. Immunological identification and distribution of PTHrP in normal and malignant tissues. Endocrinology 1991; 128:1927-37.
103. Nussbaum SR, Gaz R, Arnold A. Hypercalcemia and ectopic secretion of PTH by an ovarian carcinoma with rearrangement of the gene for PTH. N Engl J Med 1990;323:1324-8.
104. Strewler G J, Budayyr AA, Clark O, Nissenson RA. Production of PTH by a malignant tumor in a hypercalcémie patient. J Clin Endocrinol Metab 1992;76:1373-5.
105. Yoshimoto K, Yamasaki R, Sakai H, et al. Ectopic production of PTH by a small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 1989:68:97681.
106. Rizzoli R, Pache JC, Didierjean L, Bürger A, Bonjour JR A thymoma as a cause of true ectopic hyperparathyroidism. J Clin Endocrinol Metab 1994:79:912-5.
107. Sato K, Fujii Y, Kasono K, et al. Parathyroid hormone-related protein and interleukin-1 alpha synergistically stimulate bone résorption in vitro and increase the serum calcium concentration in mice in vivo. Endocrinology 1989;124:2172-8.
108. Fried RM, Voelkel EF, Rice RH, et al. Two squamous cell carcinomas not associated with humoral hypercalcemia produce a potent bone resorption-stimulatingg factor which is IL-1 alpha. Endocrinology 1989; 125:742-75.
109. Gowen M, Wood DD, Ihrie EJ, McGurie MK, Russell RG. An interleukin-1 factor stimulates bone résorption in vitro. Nature 1983;306:318-81.
110. Heath JK, Saklatvala J, Meikle MC, Atkinson SJ, Reynolds JJ. Pig interleukin-1 (catabolin) is a potent stimulator of bone résorption in vitro. Calcif Tissue Int 1985:37:95-7.
111. Gowen M, Mundy GR. Actions of recombinant Interleukin-1, interkeukin-2 and interferon-gamma on bone résorption in vivo. J Immunol 1986; 136:2478-82.
112. Sabatini M, Boyce B, Aufdemorte T, Bonewald L, Mundy GR. Infusion of recombinant human interleukin-IG cause hypercalcemia in normal mice. Proc Natl Acad Sei USA 1988;65:5235-9.
113. Boyce BL, Aufdemorte T, Garret IR, Yates AJP, Mundy GR. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989; 125:1142-50.
114. Boyce BR, Yates AJP, Mundy GR. Bolus injection of recombinant human interleukin1 cause hypercalcemia in normal mice. Endocrinology 1989;125:2780-3.
115. No\vak RA, Morrison NE, Goad DL, et al. Squamous cell carcinoma often produce more than a single bone resorption-stimulating factor: role of IL-1 alpha. Endocrinology 1990;127:3061-9.
116. Cozzolino F, Torcia M, Aldinicci D, et al. Production of IL-1 by bone marrow myeloma cells. Blood 1989;74:380-7.
117. Kawano M, Tanaka H, Ishikawa HA, et al. IL-1 accelerates autocrine growth of myeloma cells through IL-6 in humam myeloma. Blood 1989;73:2145-8.
118. Kurihara N, Bertolini D, Suda T, Akyiama Y, Roodman GD. Interleukin-6 stimulates osteoclast -like multinucleated cells formation in long term human marrow culture by inducing IL-6 release. J Immunol 1990; 144:426-30.
119. Black K, Garrett IR, Mundy GR. Chinese hamster ovarian cells transfected with murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 1991;128:2657-9.
120. De la Mata J, Uy HL, GuiseTA, et al. Interleukin-6 enhances hypercalcemia and bone résorption mediated by PTHrP in vivo. J Clin Invest 1995;95:2645-852.
121. Jilka RL, Hangoc C, Girasole G, et al. Increased osteoblast development after estrogen loss mediated by 11-6. Science 1992;257:88-91.
122. Hitoshi S, Suzuki S, Sakuta M. Elevated serum interleukin-6 in POEMS syndrome reflects activity of the disease. Intern Med 1994;33:583-7.
123. Yoneda T, Nakai M, Moruiama K, et al. Neutralizing antibodies to human IL-6 reverse hypercalcemia associated with a human squamous cell carcinoma. Cancer Res 1993;53:737-40.
124. Gomella LG, Sargent ER, Wace TP, et al. Expression of TGF-a in normal adult kidney and enhanced expression of TGF-a in renal carcinoma. Cancer Res 1989;49:69725.
125. Derinck R, Goedell DV, Ullrich A, et al. Synthesis of messenger RNAs for TGF-a and and the epidermal growth factor receptor by human tumors. Proc Natl Acad Sei USA 1987;47:707-12.
126. Smith JJ, Derinck R, Köre M. Production of TGF-a in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sei U SA 1987;84:7567-70.
127. Yates A J, Favaratto G, Aufdemorte TB, et al. Expression of human TGF-G by Chinese hamster ovarian tumors in nude mice causes hypercalcemia and increase osteoblastic bone résorption. J Bone Miner Res 1992;7:847-53.
128. Insogna KL, Stewart AF, Morris CA, Hough L, Centrella M. Native and synthetic analogues of the malignancy associated PTHrP have in vitro TGF-like activity. J Clin Invest 1989;83:1057-60.
129. Galako M, Burn JI. Hypercalcemia in patients with advanced mammary cancer. Br MedJ 1971;3:573-7.
130. Sabatini M, Bonewald L, Chavez J, et al. Production of GM-CSF by a human tumor associated with leukocytosis and hypercalcemia induces cytokine production by host cells. (Abstract) J Bone Miner Res 1989;4:149.
131. Tashjian AH, Voelkel EF, Lazzaro M, et al. TNF-G (cachetin) stimulates bone résorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology 1987;120:2029-36.
132. Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CY. Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med 1984; 100:1-6.
133. Adams JS, Fernandez M, Gacad MA, et al. Vitamin D metabolite-mediated hypercalcemia and hypercalciuria in patients with AIDS-associated lymphoma. Blood 1989:73:235-9.
134. Johnston SRD, Hammond PJ. Elevated serum parathyroid hormone related protein and 1,25-dihydroxycholecalciferol in hypercalcemia associated with adult T-cell leukemia/lymphoma. Postgrad Med J 1992;68:753-5.
135. Bataille R, Jourdan M, Ahang X, Klein B. Serum levels of IL-6, a potential myeloma cell growth factor, as reflection of disease severity in plasma cell dyscrasia. J Clin Invest 1989;84:2008-11.
136. Garrett IR, Durie BGM, Nedwin GE, et al. Production of lymphotoxin absorbing cytokine by cultured human myeloma cells. N Engl J Med 1987;317:526-32.
137. Bun ME, Brennan MF. Incidence of hypercalcemia and malignant neoplasm. Arch Surg 1980;! 15:704-7.
138. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Ensor JE, Guinée VF. Hypercalcemia of malignancy: incidence in a comprehensive cancer centre. (Abstract) Proceedings of the American Society of Clinical Oncology 1991;10:131.
139. Dodwell DJ, Abbas SK, Morton AR, Howell A. Parathyroid hormone related protein and response to pamidronate therapy for tumor induced hypercalcemia. Eur J Cancer 1991;12:1629-33.
140. Wada S, Kitamara H, Matsuura Y, et al. Parathyroid hormone-related protein as a cause hypercalcemia in a B-cell type malignant lymphoma. Intern Med 1992;31:96872.
141. Motokura T, Fukumoto S, Takahashi S, et al. Expression of parathyroid hormonerelated protein in a human T-cell lymphotropic virus type-1 infected T-cell line. Biochem Biophys Res Commun 1988;154:1182-8.
142. Walls J, Ratcliffe WA, Wowell A, Bundred HJ. Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcemia in hospital population. Clin Endocrinol 1994;41:407-13.
143. Haddad JG, Chuy KJ. Competitive protein binding radioassay for 25 hydroxycholecalciferol. J Clin Endocrinol Metab 1971;33:992-5.
144. Parfitt MA, Gallagher JC, Heaney RP, et al. Vitamin D and bone health in the elderly. AmJClinNutr 1982;36:1014-31.
145. Food and Drug Administration, OTC Report. Federal Register, March 17,1979:161649.
146. Markestad TM, Hesse V, Siebenhuner M, et al. Intermittent high dose vitamin D prophylaxis during infancy: effect on vitamin D metabolites, calcium and phosphorus. Am J Clin Nutr 1987;46:652-8.
147. Zeghoud F, Ben-Mekbi H, Djeghri N, Garabedian M. Vitamin D prophylaxis during infancy: comparison of the long term effects of three intermittent doses (15, 5, or 2.5 mg) on 25-hyrdoxyvitamin D concentrations. Am J Clin Nutr 1994;60:393-6.
148. Vieth R. The mechanisms of vitamin D toxity. Bone Miner 1990;! 1:267-72.
149. Tilyard MW, Spears GFS, Thompson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-61.
150. Massry SG, Goldstein DA. Is calcitriol [1,25(OH)2D3] harmful to renal function? JAMA 1979:242:1875-6.
151. Key LL, Anast CS. Calcitriol for congenital osteopetrosis. (Letter) N Engl J Med 1984;311:55.
152. Omdahl J, Holick M, SudaT, et al. Biological activity of 1,25-dihydroxycholecalciferol. Biochemistry 1971:10:2935-40.
153. Papapoulos SE, ClemensTL, FraherLJ, et al. 1,25-dihydroxycholecalciferol in pathogenesis of the hypercalcemia of Sarcoidosis. Lancet 1979;! :627-33.
154. Harrel GT, Fisher S. Blood chemical change in Boeck's Sarcoid with particular reference to protein, calcium, and phosphorus values. J Clin Invest 1939;18:68793.
155. Smddy PR, Bird R, Neville E, et al. Biochemical findings in Sarcoidosis. J Clin Pathol 1980;33:528-33.
156. Anderson J, Harper C, Dent CE, Philpot GR. Effect of cortisone on calcium metabolism in Sarcoidosis with hypercalcemia: possibly antagonistic action of cortisone and vitamin D. Lancet 1954;2:720-4.
157. Henneman PH, Dempsey EF, Carroll EL, Albright F. The cause of hypercalciuria in sarcoid and its treatment with cortisone and sodium phytate. J Clin Invest 1956;35:1229-42.
158. Taylor RL, Lynch HJ. Seasonal influence of sunlight on the hypercalcemia of sarcoidosis. Am J Med 1963;34:221-7.
159. Papapoulos SE, Fraher LJ, Sandier LM, Clemens TL, Lewin IG, O'Riordan JLH. 1,25-dihydroxycholecalciferol in the pathogenesis of the hypercalcemia of sarcoidosis. Lancet 1979;2:627-30.
160. Bell NH, Stem PH, Pantzer E, SinhaTK, De Luca HE Evidence that increased circulating alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in Sarcoidosis. Lancet 1979;64:218-25.
161. Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL. Hypercalcemia in an anephric patient with Sarcoidosis: evidence for extrarenal generation of 1,25dihydroxyvitamin D. N Engl J Med 1981;305:440-3.
162. Maesaka JK, Batuman V, Pablo MC, Shakamuri S. Elevated 1,25-dihydroxyvitamin D levels: occurrence with Sarcoidosis with end-stage renal disease. Arch Intern Med 1982;142:1206-12.
163. Korkor A, Gray R, Lemann J. Further evidence for extra-renal synthesis of 1,25(OH)2 vitamin D in sarcoidosis. Kidney Int 1985;27:119.
164. Adams IS, Gacad MA, Anders A, et al. Biochemical indicators of disordered vitamin D and calcium homeostasis in Sarcoidosis. Sarcoidosis 1986;3:l-6.
165. Adams JS. Vitamin D metabolite-mediated hypercalciuria. Endocrinol Metab Clin North Am 1989;18:765-78.
166. Meyrier A, Valeyre D, Bouillon R, et al. Resorptive versus absorptive hypercalciuria in sarcoidosis: correlations with 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D parameters of disease activity. Q J Med 1985;54:269-81.
167. Mason RS, FrankelT, ChanYL, Lissner D, Posen S. Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med 1984;100:59-61.
168. Adams IS, Sharma OP, Gacad MA, et al. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. I Clin Invest 1983 ;72:185660.
169. Adams IS, Singer FR, Gacad MA, et al. Isolation and structural identification of 1,25- dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. I Clin Endocrinol Metab 1985;60:960-6.
170. Reiche! H. Koeffier HP, Barbers R, Norman AW. Regulation of 1,25dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. I Clin Endocrinol Metab 1987;65:1201-9.
171. Fuss M, Gillet PC, Karmali R, Corvilain I. Calcium and vitamin D metabolism in granulomatous diseases. Clin Rheumatol 1992;! 1:28-36.
172. lackson WPV, Doncaster CD. A consideration of the hypercalcemia in sarcoidosis, idiopathic hypercalciuria, and that produced by vitamin D. I Clin Endocrinol Metab 1959:19:658-80.
173. Bell NH, Bartter FC. Studies of Ca metabolism in sarcoidosis: evidence for increased sensitivity of bone to vitamin D. Acta Endocrinol 1967;54:173-80.
174. Dwarakanathan A, Ryan WG. Hypercalcemia of sarcoidosis treated with cellulose sodium phosphate. Bone Miner 1987;2:333-6.
175. Fallon MD, Perry HM, Teitelbaum SL. Skeletal sarcoidosis with osteopenia. Metab Bone Dis Relat Res 1981 ;3:171 -4.
176. Scholz DA, Keating RF. Renal insufficiency, renal calculi and nephrocalcinosis in sarcoidosis. Am J Med 1956;21:75-84.
177. Abbasi AA, Chemplavil JK, Farah S, Muller BF, Arestein AR. Hypercalcemia in active pulmonary tuberculosis. Ann Intern Med 1979;90:324-8.
178. Sharma SC. Serum calcium in pulmonary tuberculosis. Postgrad Med J 1981 ;57:6946.
179. Davies PDO, Brown RC, Woodhead JS. Serum concentrations of vitamin D in untreated tuberculosis. Thorax 1985;40:187-90.
180. Fuss M, Karmali R, Pepersack T, et al. Are tuberculous patients at greater risk for hypercalcemia? Q J Med 1988;69:869-78.
181. Chan TYK, Chan CHS, Shek CC, Davies PDO. Hypercalcemia in active pulmonary tuberculosis and its occurrence in relation to the radiographie extent of disease. Southeast Asian J Trop Med Public Health !992;23:702-4.
182. Tan TT, Lee BC, Khalid BAK. Low incidence of hypercalcemia in tuberculosis in Malaysia. J Trop Med Hyg 1993;96:349-51.
183. Felsenfeld AJ. Drezner MK, Liach F. Hypercalcemia and elevated calcitriol in a maintenance dialysis patient with tuberculosis. Arch Intern Med 1986;146:1941-5.
184. Peces R, Alvarez J. Hypercalcemia and elevated 1,25(OH)2D3 levels in a dialysis patient with disseminated tuberculosis. Nephron 1987;46:377-9.
185. Shai F, Baker RK, Addrizzo JR, Wallach S. Hypercalcemia in mycobacterial infection. J Clin Endocrinol Metab 1972;34:251-6.
186. Adams JS, Bames PF, Modlin RL, Bikle DD. Transpleural gradient of 1,25dihydroxyvitamin D in tuberculosis pleuritis. J Clin Invest 1989;83:1527-32.
187. Cadranel J, Garabedian M, Milleron B, Guillozo H,Akolm G, HanceAJ. 1,25(OH)2D3 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcaemic patients with tuberculosis. J Clin Invest 1990;85:1588-93.
188. Saggese G, Bertelloni S, Baroncelli GI, Nero GD. Ketoconazole decreases the serum ionized calcium and 1,25-dihydroxyvitamin D levels in tuberculosis-associated hypercalcemia. Am J Dis Child 1993;147:270-3.
189. Ryzen E, Singer FR. Hypercalcemia in leprosy. Arch Intern Med 1985;145:1305-6.
190. Lee JC, Catanzaro A, Parthemore JG, Roach B, Deftos LJ. Hypercalcemia in disseminated coccidioidomycosis. N Engl J Med 1977;297:431-3.
191. Murray JJ, Heim CR. Hypercalcemia in disseminated histoplasmosis: aggravation by vitamin D. Am J Med 1985;78:881-4.
192. Kantarjian HM, Saad MF, Estey EM, Sellin RV, Samaan NA. Hypercalcemia and disseminated candidiasis. Am J Med 1983;74:721-4.
193. Jumey TH. Hypercalcemia in a patient with eosinophilic granuloma. Am J Med 1984;76:527-8.
194. Stoeckle JD, Hardy HL, Weber AL. Chronic beryllium disease. Am J Med 1969;46:54561.
195. Kozeny GA, Barbato AL, Bansai VK, Vertuno LL, Hano JE. Hypercalcemia associated with silicone-induced granulomas. N Engl J Med 1984;311:1103-5.
196. Plimpton CH, Gellhom A. Hypercalcemia in malignant disease without evidence of bone destruction. Am J Med 1956;21:750-4.
197. Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and Non-Hodgkin's lymphomas. Blood 1993;82:1383-94.
198. Davies M, Hayes ME, Yin JAL, Berry JL, Mawer EB. Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab 1994;78:1202-7.
199. Karmali R, Barker S, Hewison M, Fraher L, Katz DR, O'Riordan JLH.
200. Adams JS, Femandez M, Gacaa MA, et al. Vitamin D metabolite-mediaied hypercalciuria and hypercalciuria patients with AIDS and non-AIDS associated lymphoma. Blood 1989;73:235-9.
201. Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillae F. Calcitriol production in hypercalcaemic and normocalcaemic patients with non-Hodgkin's lymphoma. Ann Intern Med 1994; 121:633-40.
202. Fetchick DA, Bertolini DR, Sarin PS, Weintraub ST, Mundy GR, Dünn JF. Production of 1,25-dihydroxyvitamin D3 by human T cell lymphotrophic virus-1-transformed lymphocytes. J Clin Invest 1986;78:592-6.
203. Dodd RC, Winkler CF, Williams ME, Bunn PA, Gray TK. Calcitriol levels in hypermalcemic patients with adultT-cell lymphoma. Arch Intern Med 1986; 146:1971 2
204. Senba M, Kawai K. Hypercalcemia and production of parathyroid hormone-like protein in adult T-cell leukaemia-lymphoma. Eur J Haematol 1992;48:278-9.
205. Haddad JG Jr, Rojanasathit S. Acute administration of 25 hydroxycholecalciferol in man. J Clin Endocrinol Metab 1976;42:284-90
206. Kawakami M, Imawari M, Goodwin DS. Quantitative studies of the interaction of cholecalciferol (vitamin D3) and its metabolites with different genetic variants of the serum binding protein for the sterols. Biochem J 1979;179:413-23.
207. Vieth IL McCarten K, Norwich KH. Role of 25-hydroxyvitamin D3 dose in determining rate of 1,25 dihydroxyvitamin D3 production. Am J Physiol 1990;258:E780-9.
208. Haussler MR, Cordy PE. Metabolites and analogues of vitamin D: which for what? JAMA 1982;247:841-4.
209. Haussler MR. Vitamin D receptor: nature and function. Annu Rev Nutr 1986:6:52762.
210. Reinhart TA, Horst RL. Self induction of 1,25 dihydroxyvitamin D3 metabolism limits receptor occupancy and target tissue responsiveness. J Biol Chem 1989;264:15917-9.
211. Mallon JP, Mamszewski D, Sheppard H. Binding specificity of the rat serum vitamin D transport protein. J Steroid Biochem 1980;13:409-13.
212. Adams JS. Specific internalization of l ,25-dihyroxyvitamin D3 by cultured intestinal epithelial cells. J Steroid Biochem 1984:20:857-62.
213. Taylor A, Norma ME. 1,25(OH)2D levels in dihydrotachysterol-treated patients: influence on 1,25(OH)2D assays. J Bone Miner Res 1987:2:567-70.
214. Leafy TJ, Jones G, Yip A, Lohnes D, Cohanim M, Yendt ER. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 1986;315:727-30.
215. Glass AR, Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D and total serum calcium in hypercalcaemic patients. J Clin Endocrmol Miner Res 1988:66:934-8.
216. Adams JS, Sharma OP, Diz M, Endres D. Ketoconazole decreases the serum 1,25dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab 1989;70:1090-5.
217. Miller SS, Sizemore GW, Sheps SG, Tyce GM. Parathyroid function in patients with pheochromocytoma. Ann Intern Med 1975:82:372-5.
218. Stewart AF, Hoecker J, Segre GV, et at. Hypercalcemia in pheochromocytoma: evidence for a novel mechanism. Ann Intern Med 1985; 102:776-9.
219. Vemer J V, Morrison AB. Endocrine pancreatic islet disease with diarrhea. Arch Intern Med 1974;133:492-9.
220. Valentic JP, Elias AN, Weinstein GD. Hypercalcemia associated with oral isotretinon in the treatment of severe acne. JAMA 1983 ;250:1899-900.
221. Legha SS, Powell K, Beydar AV, Blumenchein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 1981;47:2803-6.
222. Mallette LE, Eichom E. Effects of lithium carbonate on human calcium metabolism. Arch Intern Med 1986; 146:770-6.
223. Heath H III. Familial benign (hypocalciuric) hypercalcemia: a troublesome mimic of mild primary hyperparathyroidism. Endocrinol Metab Clin North Am 1989;18:723-40.
224. Chou YHW, Brown EM, Levi T, et al. The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. Nature Genet 1992; 1:295-9.
225. Heath H III, Jackson CE, Otterud B, Leppert ME Genetic linkage analysis in familial benign (hypocalciuric) hypercalcemia: evidence for locus heterogeneity. Am J Hum Genet 1993;53:193-200.
226. Pollak MR, Brown EM, Chou YHW, et al. Mutation in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993;75:1297-303.
227. Minaine P, Meunier P, Edouard C, et al. Quantitative histological data on disuse osteoporosis. Calcif Tissue Res 1974;17:57-73.
228. Stewart AF, Aider M, Byers CM, et al. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med 1982;306:1136-40.
229. Chappard D, Minaire P, Privât C, et al. Effects of tiludronate on bone loss in paraplegic patients. J Bone Miner Res 1995; 10:112-8.
230. David DS, Sakai S, Brennan BL, et al. Hypercalcemia after renal transplantation: long term follow up data. N Engl J Med 1973;289:398-401.
231. Cundy T, Kanis JA, Heynen G, Morris PJ, Oliver DO. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med 1983;205:67-78.
232. Hardt LL, Rivers AB. Toxic manifestations following the alkaline treatment of peptic ulcer. Arch Intern Med 1923;31:171-80.
233. Kapener P, Langsdorf L, Marcus R, Kraemer FB, Hoffman AR. Milk-alkali syndrome in patients treated with calcium carbonate after cardiac transplantation. Arch Intern Med 1986;146:1965-8.
234. Klein GL, Horst RL, Norman AW, et al. Reduced serum 1,25-dihydroxyvitamin D during long term parenteral nutrition. Ann Intern Med 1981;94:638-42.
235. Ott SM, Maloney NA, Klein GL, et al. Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med 1983;98:910-4.
236. Edelson GW, Kleerekoper M. Hypercalcémie crisis. Med Clin North Am 1995;79:7992.
237. Mithofer K, Fernandez-del Castillo C, Frick TW, Lewandrowski KB, Rattner DW, Warshaw AL. Acute hypercalcemia causes acute pancreatitis and ectopic trypsinogen activation in the rat. Gastroenterology 1995;109:239-46.
238. Frick TW, Mithofer K, Fernandez-del Castillo C, Rattner DW, Warshaw AL. Hypercalcemia causes acute pancreatitis by pancreatic secetory block, intracellular zymogen accumulation and acinarcell injury. Am J Surg 1995; 169:167-72.
239. Nussbaum S. Pathophysiology and management of severe hypercalcemia. Metab Clin North Am 1993;22:343-61.
240. Bilezikian JP. Hypercalcemia. Dis Mon 1988;34:737-99.
241. Scarpelli DG, Tremblay G, Pearse AG. A comparative cytochemical and cytologie study of vitamin D induced nephrocalcinosis. Am J Pathol 1960;36:331-53.
242. Shetty KR, Ajiouni K, Rosenfeld PS, Hagen TC. Protracted vitmain D toxicity. Arch Intern Med 1975; 135:986-8.
243. Rizzoli R, Stoermann C, Ammann P, Bonjour JP. Hypercalcemia and hyperosteolysis in vitamin D intoxication: effects of clodronate therapy. Bone 1994;15:193-8.
244. Hefti E, Trechsel U, Fleisch H, Bonjour JP. Nature of calcémie effect of 1,25 dihydroxyvitamin D3 in experimental hypoparathyroidism. Am J Physiol 1983;244:E313-6.
245. Hass G, Truehart R, Taylor B, Stumpe M. An experimental histologie study of hypervitaminosis D. Am J Pathol 1958;3:395-422.
246. Swierczynski J, Nagel G, Zydowo M. Calcium content in some organs of rats treated with a toxic calciol dose. Pharmacology 1987;34:57-60.
247. Suki WN, Yium J J, Minden MV, et al. Acute treatment of hypercalcemia with furosemide. N Engl J Med 1970;283:836-40.
248. Gasser AB, Morgan DB, Fleisch HA, Richelle LJ. The influence of two diphosphonates on calcium metabolism in rat. Clin Sei 1972;43:31-45.
249. Bilezikian JP, Singer FR. Acute management of hypercalcemia due to PTH and PTHrP. In: Bilezikian JP, Levine MA, Marcus R, editors. The parathyroids. New York: Raven Press; 1994. p. 359-72.
250. Hosking D J, Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcemia of malignancy. Q J Med 1984;53:339-59.
251. Ralston SH, Gardner MD, Dryburg FJ, et al. Comparison of aminohydroxypropyledene diphosphate, mithramycin and corticosteroid/calcitonin in the treatment of cancer-associated hypercalcemia. Br Med J 1985;2:907-9.
252. Ralston SH, Alzaid AA, Gardner MD, Boyle IT. Treatment of cancer associated hypercalcemia with combined aminohydroxypropyledene diphosphate and calcitonin. BrMed J 1986;292:1549-50.
253. Fatemi S, Singer FR, Reide RK. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 1992;50:107-9.